Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 18/20 | 0.64 |
| ▸ | PPARA | Q07869 | 6/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185393 | 1.00 | PPARD (0.64) | PPARDPPARAALOX5PSEN1ALDH1A1 | |
| SCHEMBL4173732 | 0.86 | PPARD (0.71) | PPARDPPARAALDH1A1L3MBTL1 | |
| SCHEMBL4180994 | 0.85 | PPARD (0.74) | PPARDPPARAALDH1A1L3MBTL1 | |
| SCHEMBL4196347 | 0.80 | PPARD (0.71) | PPARDPPARAALDH1A1L3MBTL1 | |
| SCHEMBL4186857 | 0.79 | PPARD (0.70) | PPARDPPARAALDH1A1L3MBTL1 | |
| SCHEMBL4185340 | 0.79 | PPARD (0.70) | PPARDPPARAALDH1A1L3MBTL1 | |
| SCHEMBL4187458 | 0.79 | PPARD (0.69) | PPARDPPARAALDH1A1L3MBTL1 | |
| SCHEMBL4186390 | 0.79 | PPARD (0.59) | PPARDPPARAALOX5PSEN1ALDH1A1 | |
| SCHEMBL4194397 | 0.79 | PPARD (0.69) | PPARDPPARAALDH1A1L3MBTL1 | |
| SCHEMBL4182924 | 0.79 | PPARD (0.74) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-07-30 | — | — | US | claimed |
| EP-1945620-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2008-07-23 | — | — | EP | claimed |
| WO-2007056366-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | claimed |
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2009-07-30 | — | — | US | disclosed |
| EP-1945620-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007056366-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192203-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885ALOX5 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.